With a strong late-stage anti-inflammatory molecule in its pipeline, the challenge for Abivax is to garner the funds to take its obefazimod program forward. To that end, the company is continuing to do a major overhaul of personnel and is sharpening its corporate vision.
With a star pipeline candidate entering Phase III clinical trials for the treatment for ulcerative colitis, Abivax S.A. is in the midst of a corporate rework to be able to secure funding and ultimately bring its program to completion.
In a Phase IIb maintenance trial for ulcerative colitis patients released earlier this year, obefazimod, a first-in-class once-daily oral miR-124...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
